Our August 2012 pick reported some fantastic news last night. The European Committee for Medicinal Products for Human Use (CHMP) recommended approval for their groundbreaking drug. The European Medicines Agency (EMA) will issue a final decision soon -- in about three months.
There has been a good deal of negative speculation recently in the financial press, so the positive CHMP decision comes as a surprise to many. Our recommendation’s shares, which were already up some 90% in our portfolio, skyrocketed over 100% in morning trading. Right now, we are sitting on a 250% gain from our original recommendation.
↧